Phytopharm (PYM)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | n/a |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 0.80 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 30th Sep | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | TTM | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | ||||||||||
| Operating Profit | £m | ||||||||||
| Net Profit | £m | ||||||||||
| EPS Reported | p | ||||||||||
| EPS Normalised | p | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | p | ||||||||||
| Capex ps | p | ||||||||||
| Free Cashflow ps | p | ||||||||||
| Dividends | |||||||||||
| Dividend ps | p | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | £m | ||||||||||
| Working Capital | £m | ||||||||||
| Net Fixed Assets | £m | ||||||||||
| Net Debt | £m | ||||||||||
| Book Value | £m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | p | -8.8% | |||||||||
FINANCIAL BRIEF: For the six months ended 31 March 2013, Phytopharm plc revenues decreased from L17K to L0K. Net loss decreased 46% to L2.7M. Revenues reflect United Kingdom segment decrease from L66K to L0K. Lower net loss reflects Research/Development decrease of 50% to L2.4M (expense). Basic Earnings per Share excluding Extraordinary Items remained flat at -L0.01. more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Mar '13) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: |
Phytopharm plc (Phytopharm) is a development-stage pharmaceutical company. The Company’s lead programs target neurodegenerative diseases, including Parkinson’s disease, amyotrophic lateral sclerosis and glaucoma. As of September 30, 2011, Phytopharm was focused on the treatment advances in its target areas of neurodegeneration and inflammatory disease. Its lead series of compounds are the Sapogenins (including Cogane and Myogane). The Company’s products, Cogane and Myogane, are structurally related, small-molecule, chemical entities and members of the Sapogenin class of compounds. They are orally bioavailable neurotrophic factor modulators that readily cross the blood-brain barrier. Both compounds have demonstrated neuroprotective effects in a range of preclinical models.
Directors: Tim Sharpington (CEO) , Roger Hickling (Exec. Dir.) , Zoe McGowan (Secy.) ,
No. of Employees: 14 No. of Shareholders: 2,529
| Last Annual | September 30th, 2012 |
| Last Interim | March 31st, 2013 |
| Shares in Issue | 346,901,749 |
| Free Float | 324.1m (93.4%) |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | FTSE Fledgling , FTSE Fledgling XIT, FTSE Techmark All-share, |
| Exchange |
London Stock Exchange (Full) |
| Eligible for | an ISA? a SIPP? |
| Address | Lakeview House,2 Lakeview Court Ermine Business Park, HUNTINGDON, PE29 6UA, United Kingdom |
| Web | http://www.phytopharm.com/ |
| Phone | +44 1480 437697 |
| Contact | Zoe McGowan (Secy.) |
| Registrar | Equiniti Limited |
| Auditors | PricewaterhouseCoopers LLP |
| 23rd May | Interim Results |
| 21st May | Statement re. Suspension |
| 17th May | Notice of Results |
| 27th Mar | AGM Statement |
| 26th Mar | Strategic Review Update |
| 15th Mar | Holding(s) in Company |
Recent ↓
